XML 81 R37.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Commitments and Contingencies (Tables)
12 Months Ended
Dec. 31, 2019
Commitments And Contingencies Disclosure [Abstract]  
Summary of Clinical Research Organization Contracts The contracts also contain variable costs that are hard to predict as they are based on such things as patients enrolled and clinical trial sites, which can vary and therefore, are not included in the table below. The contracts held by the Company as of December 31, 2019, are summarized as follows (in thousands):

 

Indication

 

Estimated

Contractual

Obligation

as of

December 31,

2019

 

Months

Remaining

on Contract

 

HER2 Overexpressed/Amplified Breast Cancer (Extension)

$

16,402

 

 

12

 

HER2 Overexpressed/Amplified Breast Cancer (Licensor Legacy Clinical Trials)

 

695

 

 

3

 

HER2 Mutated Breast Cancer and HER2 Mutated Breast Cancer with Brain Metastases

 

697

 

 

36

 

Metastatic & Adjuvant Breast Cancer

 

24,839

 

 

6

 

Pre-Clinical Research

 

2,288

 

 

10

 

Post-Clinical Research

 

2,335

 

 

6

 

HER2 Mutated Solid Tumors

 

22,117

 

 

14

 

Other

 

28,425

 

 

19

 

Total

$

97,798